ESC 2014 Shines Spotlight On The Future Of Cardiology
The cardiology sector, long known as one of the most innovative in medtech, has a new wave of technologies on the horizon that could help reinvigorate the sector and create new multibillion-dollar market opportunities for device manufacturers. We take a closer look at these technologies, which include vagal nerve stimulation, remote monitoring for heart failure, as well as innovation in the percutaneous coronary intervention space, all of which were all in the spotlight at the recent European Society of Cardiology Congress 2014 in Barcelona.
The cardiology sector has long been one of the most innovative in medtech, with technologies such as drug-eluting stents (DES) and transcatheter aortic valves cutting down the need for more invasive open surgery.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Manufacturers of medical products would be foolish to think that recent upheavals at the US FDA will result in a lack of inspections in the coming years. A panel of experts discussed the current state of inspections during a webinar hosted by the Food and Drug Law Institute.
The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
